Cover Image
市場調查報告書

疤痕:開發中產品分析

Scar - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 199796
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
疤痕:開發中產品分析 Scar - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 89 Pages
簡介

疤痕是覆蓋在傷口上,永久性的皮膚貼片。疤痕產生於組織受損部位,為由紅到紫的堅硬纖維組織,厚度與顏色會隨著時愈來愈淡薄。

本報告提供疤痕治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

疤痕概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

大學/研究機關研究中的產品

開發治療藥的企業

  • 3M Drug Delivery Systems
  • Albireo AB
  • Altacor Limited
  • Beech Tree Labs, Inc.
  • Clanotech AB
  • Escape Therapeutics, Inc.
  • FirstString Research, Inc.
  • LegoChem Biosciences, Inc
  • Moerae Matrix, Inc.
  • Promore Pharma
  • RXi Pharmaceuticals Corporation
  • VBS Pharmaceuticals

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9068IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2017, provides an overview of the Scar (Dermatology) pipeline landscape.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Scar - Overview
  • Scar - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Scar - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Scar - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Albireo Pharma Inc
    • Altacor Ltd
    • Beech Tree Labs Inc
    • BirchBioMed Inc
    • BLR Bio LLC
    • Clanotech AB
    • Escape Therapeutics Inc
    • FirstString Research Inc
    • Kringle Pharma Inc
    • Moerae Matrix Inc
    • Pharmaxis Ltd
    • Promore Pharma
    • RXi Pharmaceuticals Corp
    • Synedgen Inc
    • VBS Pharmaceuticals
  • Scar - Drug Profiles
    • A-3914 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A-5425 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLR-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTL-slo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLT-28643 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • decorin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FibroStem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Granexin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICX-RHY - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-100IT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMI-0100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Fibrotic Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nefopam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharide for Wounds and Scars - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXL-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-34240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Lysyl Oxidase for Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tranilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Scar - Dormant Projects
  • Scar - Discontinued Products
  • Scar - Product Development Milestones
    • Featured News & Press Releases
      • Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
      • Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
      • Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
      • Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
      • Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
      • Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
      • Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
      • Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics
      • Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting
      • Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO
      • Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference
      • Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109
      • Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
      • Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
      • Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Scar, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Scar - Pipeline by 3M Drug Delivery Systems, H1 2017
  • Scar - Pipeline by Albireo Pharma Inc, H1 2017
  • Scar - Pipeline by Altacor Ltd, H1 2017
  • Scar - Pipeline by Beech Tree Labs Inc, H1 2017
  • Scar - Pipeline by BirchBioMed Inc, H1 2017
  • Scar - Pipeline by BLR Bio LLC, H1 2017
  • Scar - Pipeline by Clanotech AB, H1 2017
  • Scar - Pipeline by Escape Therapeutics Inc, H1 2017
  • Scar - Pipeline by FirstString Research Inc, H1 2017
  • Scar - Pipeline by Kringle Pharma Inc, H1 2017
  • Scar - Pipeline by Moerae Matrix Inc, H1 2017
  • Scar - Pipeline by Pharmaxis Ltd, H1 2017
  • Scar - Pipeline by Promore Pharma, H1 2017
  • Scar - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Scar - Pipeline by Synedgen Inc, H1 2017
  • Scar - Pipeline by VBS Pharmaceuticals, H1 2017
  • Scar - Dormant Projects, H1 2017
  • Scar - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Scar, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top